Skip to content
OpenCapital
Get started

Kalaris Therapeutics Inc KLRS Q4 2024 Annual earnings

Reported March 7, 2025 · Before market open

EPS-$3.64Miss by $0.88
EPS estimate-$2.76

Next report

Aug 12, 2026 (In 2 weeks)
EPS estimate-$0.50

Financials

Q4 2024

Income statement

See full
Operating income-$7.1M+88.6%
Net income-$22.0M+63.1%
EPS (diluted)-$16.33+60.0%

Balance sheet

See full
Cash & equivalents$1.6M-98.2%
Total equity-$96.6M-115%
Total assets$6.2M-96.8%

Cash flow

See full
Operating cash flow-$7.9M+74.5%

Versus estimates

Diluted EPS

Q1 2026-$0.46Beat by $0.06Q4 2025-$0.44Beat by $0.12Q3 2025-$0.64Beat by $0.02Q2 2025-$0.61Miss by $0.10Q1 2025-$2.52Miss by $1.74
Q4 2024-$3.64Miss by $0.88

Ask the moment Kalaris Therapeutics Inc reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Kalaris Therapeutics Inc report Q4 2024 earnings?
Kalaris Therapeutics Inc (KLRS) reported Q4 2024 earnings on March 7, 2025 before market open.
What were Kalaris Therapeutics Inc's Q4 2024 revenue and EPS?
Kalaris Therapeutics Inc reported eps of $-3.64 for Q4 2024.
Did Kalaris Therapeutics Inc beat estimates in Q4 2024?
EPS missed the consensus estimate of $-2.76 by $0.88.
Where can I find Kalaris Therapeutics Inc's Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-035143) directly on SEC EDGAR. The filing index links above go to sec.gov.